ReiThera to Unveil ReiCell-AAV Platform for High-Efficiency Gene Therapy AAV Production, Adding to MVA and GRAd Vector Capabilities

• First look at ReiCell-AAV next week at Advanced Therapies London, Booth 94
• With three cutting-edge platforms for gene therapy and genetic vaccine production, ReiThera remains unique among CDMOs

Rome, Italy – March 12 2025 – ReiThera, a global Contract Development and Manufacturing Organization (CDMO), is highlighting its latest vector platform, ReiCell-AAV, alongside the rest of its comprehensive portfolio at Advanced Therapies 2025 in London. ReiCell-AAV enables scalable production of AAVs, the most common vector used in commercial gene therapies. With three innovative platforms to advance viral vector-based therapies, ReiThera is building on its impressive track record in developing and manufacturing genetic vaccines and gene therapies to meet the evolving needs of the biopharmaceutical industry.

ReiThera’s ReiCell-AAV platform offers a clonal HEK-293 cell line optimized for scalable AAV vector production. Derived from a well-characterized lineage, ReiCell-AAV enables high-density suspension culture in chemically defined media, ensuring enhanced yield, safety, and regulatory compliance. Tailored for large-scale bioreactor-based production, this platform provides a seamless transition from research to clinical-grade manufacturing, supporting the growing demand for AAV-based gene therapies.

ReiCell-AAV joins two other cutting-edge platforms with impressive clinical records:

• ReiThera’s MVA (Modified Vaccinia Ankara) platform provides a robust, validated, and industry-proven technology for genetic vaccine production. With extensive expertise in MVA vector engineering and large-scale GMP manufacturing, ReiThera ensures a reliable and regulatory-compliant approach to developing vaccines for infectious diseases, immuno-oncology, and personalized therapies. Its fully validated manufacturing methodology, featuring both stirred-tank and fixed-bed bioreactors, guarantees seamless scalability from small to large production batches while maintaining the highest quality and consistency standards.
  The MVA platform has been validated in multiple clinical trials. 

• At the forefront of genetic vaccine development, ReiThera’s GRAd platform leverages a proprietary gorilla adenovirus vector with low seroprevalence in humans, making it an ideal candidate for strong and sustained immune responses in particular for CD8 T-Cell based immunity. The GRAd platform has demonstrated thermostability, high immunogenicity, and efficient scalability up to 2000L scale, making it a powerful choice for next-generation vaccines. With an established GMP manufacturing process and validated quality control measures, ReiThera provides a reliable and scalable solution for vaccine developers worldwide.
  
  A GRAd-based vaccine against SARS-CoV2 has been found safe and effective through multiple clinical trials, and a new clinical trial funded by Bill & Melinda Gates Foundation recently launched to test a GRAd-based vaccine for HIV.

ReiThera’s expertise in viral vector production has positioned the company as a trusted partner for biotech and pharmaceutical companies worldwide. From early-stage process development to GMP manufacturing and regulatory support, ReiThera offers end-to-end solutions to accelerate the development of genetic vaccines and gene therapies.

"With our ReiCell-AAV, MVA, and GRAd platforms, ReiThera continues to lead innovation in viral vector manufacturing," said Claudio Panzarella, Head of Business Development at ReiThera. "We are committed to providing high-quality, scalable, and regulatory-compliant solutions that empower our partners in the fight against infectious diseases and genetic disorders. Our platforms are not only technologically advanced but also designed to offer cost-effective solutions for our clients. All our platforms are available for new collaborations, and we look forward to presenting them to interested partners at Advanced Therapies London, at Booth 94!”

About ReiThera SRL

ReiThera Srl is a CDMO dedicated to technology and process development and GMP manufacturing, providing support for the clinical translation of genetic vaccines and medicinal products for advanced therapies.

The company has extensive expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAV), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Ankara (MVA) and Herpes Simplex Vector.

ReiThera's core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, as well as fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.

ReiThera's headquarters, R&D laboratories, and GMP facilities are located in Rome, Italy. For more information, visit www.reithera.com